Drugs / Iadademstat
Iadademstat
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07113691 | Jan 2026 → Jan 2030 expected | small cell lung carcinoma | Yale University | Recruiting | No outcome recorded |
| Phase 1 | NCT06502145 | Jan 2025 → Dec 2026 expected | myelodysplastic syndrome | Medical College of Wisconsin | Recruiting | No outcome recorded |
| Phase 1 | NCT06514261 | Dec 2024 → Sep 2026 | acute myeloid leukemia | National Cancer Institute (NCI) | Suspended | No outcome recorded |
| Phase 1 | NCT06357182 | Aug 2024 → Mar 2027 expected | acute myeloid leukemia | OHSU Knight Cancer Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT05546580 | Nov 2022 → Nov 2025 overdue | acute myeloid leukemia | Oryzon Genomics S.A. | Recruiting | No outcome recorded |
| Phase 1 | NCT02913443 | Dec 2016 → Oct 2017 | small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06287775 | Apr 2025 → Jul 2029 expected | small cell lung carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06661915 | Aug 2025 → Dec 2027 | acquired polycythemia vera, essential thrombocythemia, leukemia, myeloid, accelerated-phase, myelodysplastic/myeloproliferative neoplasm +3 | National Cancer Institute (NCI) | Suspended | No outcome recorded |
| Phase 2 | NCT05420636 | Dec 2022 → Jul 2025 | small cell lung carcinoma | Fox Chase Cancer Center | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iadademstat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06661915 ↗ |
| Known as | IADA | “iadademstat (IADA) when administered as part of the investigational combination” NCT06357182 ↗ |
| Known as | ORY-1001 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3781751 ↗ |
| Known as | RG-6016 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3781751 ↗ |
| Known as | RO7051790 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02913443 ↗ |
| Action | Inhibit | “Iadademstat inhibits the LSD1 protein and may lead to inhibition of cell growth in LSD1-overexpressing cancer cells.” NCT06357182 ↗ |
| Modality | Small molecule | — CHEMBL3781751 ↗ |
| Route | Oral | “RO7051790 will be given orally.” NCT02913443 ↗ |